A critical limitation of standard curcumin supplements is poor oral bioavailability: at a 2 g oral dose taken alone, human serum curcumin is undetectable or negligible — around 0.006 µg/mL at one hour — because of poor absorption, rapid metabolism, and fast elimination. The most established solution is co-administration with piperine (black pepper extract), which raised human curcumin bioavailability by 2,000% at 45 minutes; a commonly used regimen is 500 mg of curcumin with 5–6.7 mg of piperine three times a day. The other frequently tested approach is combining curcumin with lipids, as in Meriva® (a curcumin–phosphatidylcholine complex) and BCM-95® (curcumin with turmeric essential oils). Because curcumin ingested alone is poorly absorbed, the formulation matters as much as the dose.
The strongest clinical evidence is for knee osteoarthritis (OA). A systematic review and meta-analysis of 10 RCTs covering 786 patients found that Curcuma longa significantly reduced VAS pain against placebo (mean difference 18.25, 95% CI 7.79–28.72, p = 0.0006), and the benefit held in both the under-1,000 mg/day and the 1,000 mg/day-or-more subgroups. Pooled WOMAC total score, by contrast, did not separate from placebo (mean difference 8.12, 95% CI −2.11–18.35, p = 0.12), so the pain finding rests on firmer ground than the function finding. Against active comparators, turmeric was non-inferior rather than superior on WOMAC total, and it was better tolerated: one trial recorded adverse effects in 13% of the curcumin arm versus 38% on diclofenac, and a 367-patient multicentre study of Curcuma domestica extract against ibuprofen reported significantly more abdominal pain and discomfort in the ibuprofen group. The caveats are substantial: heterogeneity was extreme (I² of 98–99% for both pooled outcomes), funnel plots for both were asymmetric, and the pooled follow-up ran only 4 to 6 weeks.
Curcumin modulates inflammatory pathways relevant to mood: it inhibits NF-κB and lowers IL-6 and TNF-α. Examine’s evidence summary states that curcumin can alleviate symptoms of depression, and its database covers depression across 6 outcomes in 9 studies, with major depressive disorder tracked separately — including several randomized trials that added curcumin to existing antidepressant treatment rather than using it alone. None of the sources cited on this page quantify the size of that effect or establish a guideline-endorsed dose for mood, so curcumin belongs in the adjunct column rather than as a substitute for established treatment.
Curcumin inhibits TNF-α, IL-1, IL-1β, IL-6, IL-8, and COX-2, suppressing prostaglandin synthesis. This overlaps with the mechanism of NSAIDs but runs through a distinct pathway: curcumin’s comparatively good gastrointestinal tolerability is attributed to NF-κB inhibition reducing COX-2 rather than to COX-1 blockade. In humans, a meta-analysis of 13 RCTs of curcumin co-administered with piperine found significant decreases in TNF-α, IL-6, and malondialdehyde alongside significant increases in superoxide dismutase activity and glutathione. Two of that review’s co-authors are affiliated with commercial producers of curcumin and piperine supplements, which is worth weighing against the result.
The cancer evidence is preclinical. In animal models, oral curcumin inhibited tumor formation in lung, skin, oral and head-and-neck, hepatocellular, mammary, and lymphoma/leukemia models as well as adenomatous polyposis, and topical curcumin reduced UVB-induced tumor counts and delayed the onset of tumorigenesis. That breadth has not carried over into comparable human evidence: the sources cited on this page establish no clinical cancer-prevention effect, and Examine’s database covers only colorectal cancer (1 outcome across 2 studies) and prostate cancer (6 outcomes across 2 studies), with cancer absent from the benefits it summarizes for curcumin. The bioavailability problem remains the major barrier to clinical translation.
Trial doses span 300 mg to 4,000 mg per day depending on the condition. Common enhanced-formulation regimens are 1,500 mg/day of curcumin with 15–20 mg/day of piperine split across three doses, 1,000 mg/day of BCM-95®, or 400–1,000 mg/day of Meriva®. In the knee OA meta-analysis, both the under-1,000 mg/day and the 1,000 mg/day-or-more subgroups beat placebo on VAS pain, so more is not obviously better. Curcumin is usually taken alongside food.